The Chlamydia Infection Diagnostics Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The historical growth trend in the Chlamydia Infection Diagnostics market has seen it expand from $1.25 billion in 2024 to $1.4 billion in 2025, growing at a compound annual growth rate (CAGR) of 11.9%.
The projected market size for chlamydia infection diagnostics in 2029 is expected to reach $2.16 billion, with a compound annual growth rate (CAGR) of 11.5%.
Download Your Free Sample of the 2025 Chlamydia Infection Diagnostics Market Report and Uncover Key Trends Now!The drivers in the chlamydia infection diagnostics market are:
• Rising awareness and education about sexually transmitted infections
• Increased government funding for diagnostic research
• Growth in cases of sexually transmitted infections
• Improved healthcare accessibility for diagnostic services
The chlamydia infection diagnostics market covered in this report is segmented –
1) By Test Type: Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test, Other Test Types
2) By Type Of Infections: Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection
3) By Application: Hospitals, Specialty Clinics, Diagnostic Centers
4) By End User: Diagnostics, Therapeutics
The trends in the chlamydia infection diagnostics market are:
• Advancements in molecular diagnostics are shaping the future of the chlamydia infection diagnostics market.
• The expansion of point-of-care testing (POCT) is a significant emerging trend.
• The integration of digital health technologies is increasingly influencing the future of the market.
• The focus on population screening and public health initiatives is a growing trend.
The major players in the chlamydia infection diagnostics market are:
• Roche Diagnostics
• Thermo Fisher Scientific Inc.
North America was the largest region in the chlamydia infection diagnostics market in 2024